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Introduction
 The aim of this study was to objectively evaluate the effects of a single intra-articular (IA)
injection of high concentrated (88 mg) and high molecular weight (HMW) hyaluronic acid (HA) in
horses with clinical osteoarthritis (OA).
  
Materials and Methods
 OA was diagnosed through lameness evaluation, anaesthetic blocks and digital radiographic
examination. Lameness examination was performed subjectively and asymmetry was measured
objectively using an inertial sensor device at weeks 1, 2, 4 and 8 after treatment. Synovial fluid
(SF) analysis (viscosity, total protein (TP), and cytological examination) were evaluated before
treatment and at the end of the study.
  
Results
 Eight horses were included. One week after treatment 6 individuals subjectively improved, being
significantly less lame (P = 0.020), but only 2 remained clinically better after two months.
Subjective flexion test response improved in 4 horses at week 8.
 Decreased asymmetry was observed in a straight line (week 1), after flexion in the forelimbs
(week 1 and 2) and in the hind limbs (week 8) (P = 0.016). Synovial fluid showed significant
reduction in TP at the end of the study (P = 0.042).
  
Discussion/Conclusion
 In conclusion, a single 88 mg HMW-HA is safe, induces modest improvement in subjective
lameness and asymmetry and reduces TP in SF. This could represent an alternative, in the
short-term period, to drugs that are prohibited in competition for pain relief while preserving joint
metabolism. A randomised, double blind, controlled study to further evaluate this therapy is
warranted.
